AstraZeneca: results, guidance and obesity pipeline
What AstraZeneca has reported about its sales and outlook, and where its obesity medicines stand in the trial list it published the same day. Every figure is dated and linked to where it came from.
Last checked . Figures are company-reported, in US dollars, unless a line says otherwise. This is not investment advice. For the wider field see the pipeline.
The first two tiles and the results date come from AstraZeneca's results announcement. The stage comes from its clinical trials appendix, as of October 30, 2026.
Nine months and third quarter 2026, reported October 30
AstraZeneca reported total revenue of $46,881 million for the first nine months, up 8% at actual exchange rates and 7% at constant rates, from $43,236 million. Third-quarter total revenue was $16,209 million, up 7% from $15,191 million, at both actual and constant rates.
| Period | 2026 | 2025 | Change at actual rates | Change at constant rates |
|---|---|---|---|---|
| First nine months | $46,881 million | $43,236 million | +8% | +7% |
| Third quarter | $16,209 million | $15,191 million | +7% | +7% |
Source: AstraZeneca 9M and Q3 2026 results and results announcement (PDF), October 30, 2026.
AstraZeneca's 2026 guidance
AstraZeneca reconfirmed its 2026 guidance at constant exchange rates: total revenue growth in the mid-to-high single-digit percent range and core earnings per share growth in the low double-digit percent range. Its results page also gives a core tax rate of 18% to 22%. The company says it intends to publish its full-year and fourth-quarter 2026 results on February 9, 2027.
Obesity programs in the trial appendix
The results announcement itself does not discuss obesity. The clinical trials appendix published the same day does, with the stage of each program as of October 30, 2026. The appendix gives the names below. Where a program has an older code, the Atlas tracker may still show it.
| Medicine | Type | Stage listed | Notes |
|---|---|---|---|
| Elecoglipron | Oral GLP-1 receptor agonist | Phase III in weight management (EMBOLD, EMBOLD-Asia). First dosing is listed for the third quarter of 2026 and data after 2027. Type 2 diabetes, kidney disease and heart failure studies are also listed. | Phase IIb studies VISTA (obesity or overweight) and SOLSTICE (type 2 diabetes) met their primary endpoints. |
| Lenbelintide (AZD6234) | Selective amylin receptor agonist | Phase III: SELENE-1 and SELENE-3 (obesity or overweight) and SELENE-2 (type 2 diabetes with obesity). First dosing is listed for the third quarter of 2026 and data after 2027. | Earlier phase II studies APRICUS and ARAY also appear. |
| AZD9550 with AZD6234 | GLP-1 and glucagon agonist plus an amylin agonist | Phase IIb (ASCEND), obesity | Readout listed for the third quarter of 2026. |
| AZD1043 | Antibody against the activin type II receptor, for weight management | Phase I, initiating | Early stage. |
On elecoglipron, AstraZeneca's June 8, 2026 release reports that at 75 mg in VISTA the average weight reduction was 10.5% at 26 weeks, against 0.6% with placebo, and 11.8% at 36 weeks, against 0.3%. These are changes from baseline in each group, not placebo-adjusted differences. In SOLSTICE (404 people with type 2 diabetes), HbA1c fell 1.9% from baseline at 26 weeks on 75 mg, against 0.2% with placebo.
Sources: results clinical trials appendix (PDF) and AstraZeneca elecoglipron release.
Coming up
- February 9, 2027: AstraZeneca says it intends to publish full-year and fourth-quarter 2026 results.
- After 2027: data from the phase III elecoglipron and lenbelintide weight-management studies, as listed in the appendix.
Questions about AstraZeneca's results
Did AstraZeneca confirm its 2026 guidance?
Yes. On October 30, 2026, it reconfirmed total revenue growth in the mid-to-high single-digit percent range and core earnings per share growth in the low double-digit percent range, both at constant exchange rates.
Did the results announcement mention obesity?
The announcement text does not discuss AstraZeneca's obesity programs. The clinical trials appendix published alongside it lists them, including phase III programs for elecoglipron and lenbelintide.
What is lenbelintide?
The appendix lists lenbelintide (AZD6234) as a selective amylin receptor agonist, now in phase III. Amylin is a hormone released with insulin that slows stomach emptying and signals fullness. See the cagrilintide page for another amylin medicine.
Sources
- AstraZeneca, 9M and Q3 2026 results, October 30, 2026. Company-reported figures.
- AstraZeneca, 9M and Q3 2026 results announcement (PDF), October 30, 2026. Company-reported.
- AstraZeneca, 9M and Q3 2026 results clinical trials appendix (PDF), as of October 30, 2026. Company-reported pipeline stages.
- AstraZeneca, Elecoglipron, an oral small-molecule GLP-1 RA, moves to phase III programme, June 8, 2026. Company release.
- AstraZeneca, results announcement furnished on Form 6-K, filed with the SEC. Company filing, used to cross-check the figures.